Acute Myeloid Leukemia with NPM1 Mutation

Acute Myeloid Leukemia with NPM1 Mutation — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 4
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Kura Oncology, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05886049	A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease	recruiting	Phase 1	38	National Cancer Institute (NCI)NIH	1	Aug 25, 2026	clinicaltrials
NCT06001788	Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia	recruiting	Phase 1	171	Kura Oncology, Inc.INDUSTRY	3	Aug 20, 2026